You’ve ignited your Health Tech idea, now, fuel it further. While financing is key, expert advice and deepened market knowledge provide a priceless competitive advantage. As Debiopharm’s strategic corporate fund, we not only invest but also provide strategic guidance to startups transforming Pharma R&D and cancer care. Access our launchpad towards success and go beyond funding—tap into our pharma expertise and network. Join our roster of scalable, investment-ready companies shaping the future for patients globally. Your next step is just a click away!
WE INVEST IN START-UPS POWERING PHARMA R&D TRANSFORMATION AND CANCER CARE INNOVATION
We are a strategic fund dedicated to advancing drug development. Aligned with Debiopharm’s mission, we invest in technologies that predict, enhance, and speed up the drug development process as well as those that improve the patient experience. Our focus is in oncology, so sometimes we simply call it “Cancer Tech”.
We invest in 3 main areas:
- Next Gen Pharma R&D where big data, predictive models and computational approaches augmented by AI converge to improve success rates at each stage of the drug development cycle.
- Clinical Trial Tech where new technology solutions facilitate patient-centric clinical trials, and new business models challenge traditional approaches.
- Digital Medicine where the patient journey is empowered by digital technologies, and individualised care is enabled by novel clinical insights uncovered from real-world data.
Our vision: the convergence of research and patient care
We believe that precision medicine starts with precision R&D, moving away from generic approaches to more personalised, biomarker-guided development.
We envision patient-centric clinical trials, with more patients able to access novel treatments earlier.
We imagine the emergence of AI-powered care, enabling earlier diagnosis, more precise prognosis, and truly individualised treatment pathways.
INVESTMENT CRITERIA
Early Seed – our springboard for start-ups in their 1st round of financing
- Investment round Pre-Seed / Seed - Our initial investment is < $ 1M
- Equity round or convertible notes / SAFE
- Learning opportunity for the fund & start-up ahead of potential Series A
Series A – our flagship vehicle to help scale successful start-ups
- Investment round Series A - our initial investment can be in the range of $3M – 5M
- Commercial Stage and revenue generating. Large pilots and early clients to validate commercial interest
WHAT WE LOOK FOR IN A COMPANY
We like to see a convergence of robust understanding of science, a disruptive technology or business model, and an ability to surface meaningful data-driven insights.
- Management team with entrepreneurial and industry experience
- Innovative technology
- Product answering a need with a clear USP. Market with tangible entry barriers
- Well defined operational plan and commercial strategy with a realistic budget
WHAT WE BRING AS INVESTORS
We grant our start-ups access to Debiopharm’s wealth of expertise by facilitating connections between start-ups and our internal experts. This enables startups to test their hypotheses and build more fit-for-purpose solutions, often leading to new collaborations.
Having led or co-led most of our Series A investment rounds, we are able to provide access to an extended network of investors and strategic partners.